A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6

NCT02791256 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: Ribavirin
DRUG: peginterferon alfa-2a

Sponsor

Hoffmann-La Roche